Drugs / ShigActive
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05182749 | Feb 2023 → Dec 2024 overdue | shigellosis | Intralytix, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ShigActive | “ShigActive is a collection of bacteriophages.” NCT05182749 ↗ |
| Action | Inhibit | “ShigActive is intended to significantly reduce or eliminate Shigella levels in the human gastrointestinal tract” NCT05182749 ↗ |
| Modality | Other / unclassified | “ShigActive is a collection of bacteriophages.” NCT05182749 ↗ |
| Route | Oral | “bacteriophage preparation given orally three times a day” NCT05182749 ↗ |